PR - Non-Invasive Monitoring Systems, Inc. (NIMS) Announces Patent Issued on Non-Invasive Means to Treat Ailments in Horses
Tuesday June 12, 1:57 pm ET
NORTH BAY VILLAGE, Fla.--(BUSINESS WIRE)--Gary Macleod, Chief Executive Officer, Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU - News) announced that the US Patent Office issued Patent 7,228,576 on June 12, 2007 entitled, "Reciprocating movement platform for the external addition of pulses to the fluid channel of a subject."
Macleod added: "This patent is a continuation of US patent 7,311,346 issued in 2006 which dealt with our motion platform applications in human subjects. This new patent discloses motion platform applications in horses and further protects the value of the Company's flagship products (AT-101(TM) and Exer-Rest(TM)) for therapeutic and diagnostic applications that have already been published in peer-reviewed research studies as well as for future products and applications."
Dr. Marvin Sackner, Chairman of the Board of Directors as well as co-inventor with D. Michael Inman, stated: "it is well established that many beneficial effects of exercise relate to release of mediators into the circulation. The technology disclosed in this patent is a non-invasive, drug-free means to cause release of these beneficial mediators to approximately the same blood levels as exercise in resting animals. Such mediators include nitric oxide, prostacyclin, and tissue plasminogen activator (tPA), among others. Research findings in large animal models corroborating this action have been published by Dr. Jose A. Adams and associates at Mount Sinai Medical Center of Greater Miami."
"Our motion platform has been designed to support a standing horse held in position with a sling such that its body is passively moved repetitively head to tail over a period of 30 to 45 minutes. Such motion adds smaller amplitude pulses to the natural pulse at the frequency of the platform movements thereby providing beneficial effects due to release if the same mediators that occur during exercise."
"The motion platform has potential to treat such ailments in horses as osteoarthritis, colic, heaves, chronic obstructive pulmonary disease and exercise induced pulmonary hemorrhage.
The "Exer-Rest(TM)" for human applications is not currently being sold in the United States pending FDA approval before sales commence.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
Contact:
Non-Invasive Monitoring Systems, Inc., North Bay Village
Gary Macleod, 305/861-0075
gmacleod@nims-us.com
--------------------------------------------------------------------------------
Source: Non-Invasive Monitoring Systems, Inc.
AI
